# A national non-profit contract research organisation for academic oncology trials

Source: https://onco.cc/ideas/idea-fund-public-nonprofit-cro/  
OnCo record `idea-fund-public-nonprofit-cro` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Running an early trial properly requires monitors, data managers, safety reporting and regulatory filings that universities cannot afford from commercial providers. A public not-for-profit would do this work at cost.

## Summary

A publicly-owned or non-profit CRO providing sponsor-level services (protocol development, regulatory submissions, monitoring, pharmacovigilance, data management, statistics) to academic phase 1 and 2 oncology trials at cost, funded partly by a core grant and partly by fees charged to grants. Academic trials fail or stall for operational, not scientific, reasons; commercial CRO fees consume a large share of academic trial budgets. Precedents include the UK's NIHR clinical research network infrastructure, the EORTC headquarters model for European academic trials, and NCI's CTEP for investigational agents.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Academic trials supported by a non-profit CRO complete recruitment and report results at least 30% faster than academic trials using commercial or in-house ad hoc support, at lower total cost per patient.
- Rationale: EORTC and the German and UK cooperative trials units show that shared professional infrastructure lifts completion rates and quality; a non-profit CRO extends this from cooperative-group phase 3 to the early-phase academic trials where the valley of death is deepest.
- Proposed test: Fund a pilot CRO to sponsor twenty academic phase 1/2 oncology trials and compare start-up time, recruitment velocity, protocol deviations and reporting time against a matched set of contemporaneous academic trials.
- Maturity: speculative
- Actor: policy

## Sources

- Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008): https://doi.org/10.1038/453840a

## Connected records

- ideas: [A global first-in-human network for academic cancer trials with single ethics review](https://onco.cc/ideas/idea-fund-global-academic-phase-one-network/), [A public indemnity pool so universities can sponsor first-in-human cancer trials](https://onco.cc/ideas/idea-fund-academic-sponsor-indemnity-pool/), [Regional translational institutes with academic GMP suites and IND teams](https://onco.cc/ideas/idea-fund-translational-institutes-gmp/)
- companies: [EORTC](https://onco.cc/companies/curie-nki-eortc/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- bottlenecks: [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/), [Trial design, endpoints and cost](https://onco.cc/bottlenecks/b-trial-design/)
- key papers: [Reproducibility Project: Cancer Biology found that landmark preclinical results mostly shrank or vanished on replication](https://onco.cc/key-papers/paper-reproducibility-project-cancer-biology-elife-2021/), [Translational research: crossing the valley of death](https://onco.cc/key-papers/paper-butler-nature/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-public-nonprofit-cro.json